A Multicenter, Randomized, Controlled Phase IIb Trial of Avoidance of Hyperoxemia during Cardiopulmonary Bypass

Shay P McGuinness1, Rachael L Parke, Kate Drummond

  • 1From the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland, New Zealand (S.P.M., R.L.P.); Medical Research Institute of New Zealand, Wellington, New Zealand (S.P.M., R.L.P.); ANZIC-Research Centre, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (S.P.M., R.L.P., M.B.); Royal Adelaide Hospital, Adelaide, South Australia (K.D.); Clinical Perfusion, Green Lane Cardiothoracic Surgical Unit, Auckland City Hospital, Auckland, New Zealand (T.W.); and Department of Anaesthesiology, University of Auckland, Auckland, New Zealand (T.W.)Auckland City Hospital, Auckland, New ZealandAuckland City Hospital, Auckland, New ZealandAuckland City Hospital, Auckland, New ZealandAuckland City Hospital, Auckland, New ZealandAuckland City Hospital, Auckland, New ZealandCalvary Wakefield Hospital, Adelaide, South Australia.

Anesthesiology
|July 13, 2016
PubMed

Insights

Avoiding arterial hyperoxemia during cardiopulmonary bypass (CPB) did not reduce acute kidney injury (AKI) or other organ damage in cardiac surgery patients. This intervention did not impact mechanical ventilation duration or hospital stay.

Area of Science:

  • Cardiology
  • Critical Care Medicine
  • Nephrology

Background:

  • Cardiac surgery with cardiopulmonary bypass (CPB) is common.
  • Cardiac surgery-associated multiorgan dysfunction (CSA-MOD) includes acute kidney injury (AKI), hepatic, myocardial, and neurologic damage.
  • CPB-induced oxidative stress and reactive iron species contribute to CSA-MOD.

Purpose of the Study:

  • To determine if avoiding arterial hyperoxemia during CPB decreases oxidative stress.
  • To assess if avoiding arterial hyperoxemia reduces CSA-MOD severity in cardiac surgery patients.

Main Methods:

  • Multicenter, open-label, randomized controlled study.
  • Compared avoidance of arterial hyperoxemia versus usual care in CPB patients.
  • Primary outcome: incidence and severity of AKI; Secondary outcomes: CSA-MOD biomarkers, ventilation duration, and length of stay.

Main Results:

  • 298 patients randomized; mean PaO2 differed between groups during CPB.
  • No significant difference in AKI incidence (72.0% vs. 66.2%).
  • No difference in other organ damage markers or length of intensive care and hospital stay.

Conclusions:

  • Avoiding modest arterial hyperoxemia during CPB did not reduce AKI.
  • The intervention showed no benefit in reducing organ damage markers or length of stay.
Abstract